MLAB
Mesa Laboratories, Inc.
MLAB's outlook is improving, though it still trails on the overall score.
PLTR
Palantir Technologies Inc.
PLTR has the edge over MLAB overall, supported by stronger fundamentals and stronger modeled upside.
MLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Healthy |
MLAB's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
PLTR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
PLTR's revenue, profitability, cash flow and balance sheet are all currently strong.
MLAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $135 | — |
| Current | 118x | $135 | — |
| Cheap | 142x | $163 | +20% |
| Fair | 301x | $346 | +156% |
| Expensive | 570x | $656 | +385% |
Historical ranges are pointers, not guarantees.
MLAB's PE is in its cheap range at 118x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
PLTR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 75x | $172 | — |
| Current | 120x | $172 | — |
| Cheap | 165x | $236 | +37% |
| Fair | 251x | $359 | +109% |
| Expensive | 452x | $646 | +277% |
Historical ranges are pointers, not guarantees.
PLTR has the edge over MLAB in the historical PE scenario, which offers more potential upside but is not a forecast.
MLAB Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLAB's earnings to grow and its profitability to improve, with its revenue holding steady.
PLTR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
PLTR has the edge over MLAB on the outlook, with more favorable revenue expectations.
MLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.01 | +858% |
| Q3 2026 | $1.15 | +$1.46 |
| Q2 2026 | $0.85 | +$0.98 |
| Q1 2026 | $1.21 | +$1.57 |
| Q4 2025 | $0.65 | +$46.97 |
| Q3 2025 | -$0.31 | +$45.31 |
| Q2 2025 | -$0.13 | +$46.35 |
| Q1 2025 | -$0.36 | +$46.84 |
| Q4 2024 | -$46.32 | -25833% |
MLAB has returned to profit: it earned $1.15 per share over the past year, after losing money the year before.
PLTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.30 | +61% |
| Q3 2026 | $1.43 | +240% |
| Q2 2026 | $1.17 | +290% |
| Q1 2026 | $0.89 | +287% |
| Q4 2025 | $0.63 | +232% |
| Q3 2025 | $0.42 | +110% |
| Q2 2025 | $0.30 | +76% |
| Q1 2025 | $0.23 | +92% |
| Q4 2024 | $0.19 | +111% |
PLTR has the edge over MLAB on earnings, with more consistent year-over-year improvement.
MLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | +2.6% |
| Q2 2026 | $60.1M | +1% |
| Q1 2026 | $63.7M | +2.6% |
| Q4 2025 | $65.1M | +3.6% |
| Q3 2025 | $60.7M | +5% |
| Q2 2025 | $59.5M | +2.4% |
| Q1 2025 | $62.1M | +5.5% |
| Q4 2024 | $62.8M | +18% |
MLAB's revenue has grown year over year for 11 quarters in a row: $62M last quarter, up 2.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +5.7 points |
| Q2 2026 | 12% | +6.5 points |
| Q1 2026 | 4.3% | +1.9 points |
| Q4 2025 | 12% | +3.1 points |
| Q3 2025 | 7.8% | +1.7 points |
| Q2 2025 | 5.2% | -4.4 points |
| Q1 2025 | 2.4% | +463 points |
| Q4 2024 | 9.2% | +9.3 points |
MLAB's operating margin was 13% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2019.
PLTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3B | +96% |
| Q2 2026 | $1.9B | +93% |
| Q1 2026 | $1.6B | +85% |
| Q4 2025 | $1.4B | +70% |
| Q3 2025 | $1.2B | +63% |
| Q2 2025 | $1B | +48% |
| Q1 2025 | $883.9M | +39% |
| Q4 2024 | $827.5M | +36% |
PLTR has the edge over MLAB on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 47% | +14 points |
| Q2 2026 | 47% | +20 points |
| Q1 2026 | 46% | +26 points |
| Q4 2025 | 41% | +40 points |
| Q3 2025 | 33% | +18 points |
| Q2 2025 | 27% | +11 points |
| Q1 2025 | 20% | +7.2 points |
| Q4 2024 | 1.3% | -9.5 points |
PLTR has the edge over MLAB on profitability, with a higher operating margin.
MLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7M | -48% |
| Q2 2026 | $14.2M | +1504% |
| Q1 2026 | $13.5M | +14% |
| Q4 2025 | $18M | +2.2% |
| Q3 2025 | $7.1M | +105% |
| Q2 2025 | $884K | -91% |
| Q1 2025 | $11.9M | -3.6% |
| Q4 2024 | $17.6M | +69% |
MLAB generated $49M in free cash flow over the past year, up 32% from the year before.
PLTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +139% |
| Q2 2026 | $1.2B | +126% |
| Q1 2026 | $891.8M | +193% |
| Q4 2025 | $764M | +67% |
| Q3 2025 | $500.9M | +20% |
| Q2 2025 | $531.6M | +276% |
| Q1 2025 | $304.1M | +140% |
| Q4 2024 | $457.2M | +54% |
PLTR has the edge over MLAB on cash flow, with more consistent year-over-year improvement.
MLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3K shares |
| 1 year | +4.1% | +225K shares |
| 3 years | +6.9% | +373K shares |
| 5 years | +7.8% | +416K shares |
| Available history | +32% | +1.4M shares |
MLAB has 6M diluted shares, up 4.1% from a year ago.
PLTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +5.2M shares |
| 1 year | +0.1% | +2.9M shares |
| 3 years | +11% | +248M shares |
| 5 years | +31% | +610M shares |
| Available history | +184% | +1.7B shares |
PLTR has the edge over MLAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $19.2M |
| Q3 2025 | $19.2M |
| Q2 2025 | $18.6M |
| Q1 2025 | $18M |
| Q4 2024 | $18.6M |
| Q3 2024 | $18.9M |
| Q2 2024 | $17.7M |
| Q1 2024 | $9M |
MLAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q3 2023 | -1.0x | Net Cash |
MLAB's net debt is about 1.4 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
PLTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -6.1x | Net Cash |
PLTR has the edge over MLAB on leverage, with a lower net debt burden relative to earnings.
MLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 72.9 | Neutral |
MLAB's weekly RSI is 65 (neutral) and its Stochastic is 73 (neutral).
PLTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 47.4 | Neutral |
PLTR's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
MLAB PE vs Technology Sector
| Metric | MLAB | Sector median | Relative |
|---|---|---|---|
| PE | 118x | 28x | 322% above |
| PE % | 12 | 35 | 23 pts below |
MLAB has the edge over PLTR on valuation relative to its sector.
PLTR PE vs Technology Sector
| Metric | PLTR | Sector median | Relative |
|---|---|---|---|
| PE | 120x | 28x | 331% above |
| PE % | 1 | 38 | 37 pts below |
PLTR is trading at 120x earnings, a 331% premium to the Technology sector's median of 28x.
MLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 4.4% above |
| 20 week MA | $118.6 | 14% above |
| 50 week MA | $102.2 | 32% above |
| 100 week MA | $101.9 | 33% above |
| 200 week MA | $112.8 | 20% above |
MLAB has the edge over PLTR on trend strength, trading above more of its moving averages.
PLTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $185.8 | 7.6% below |
| 20 week MA | $167.6 | 2.4% above |
| 50 week MA | $157.1 | 9.2% above |
| 100 week MA | $143.8 | 19% above |
| 200 week MA | $83.3 | 106% above |
PLTR's trend is up, with a small recent dip: it's below only its 8-week average, and 106% above its 200-week average.
MLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $247.3 | $284.8 | +15% |
| 2021 | $284.8 | $328.9 | +15% |
| 2022 | $328.9 | $162.8 | -50% |
| 2023 | $162.8 | $104.8 | -36% |
| 2024 | $104.8 | $133.1 | +27% |
| 2025 | $133.1 | $80.5 | -40% |
| 2026 YTD | $80.5 | $135.2 | +68% |
MLAB has the edge over PLTR on returns for 2026, with the stronger performance.
PLTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.20 | $27.8 | +202% |
| 2021 | $27.8 | $18.9 | -32% |
| 2022 | $18.9 | $6.29 | -67% |
| 2023 | $6.29 | $17.2 | +173% |
| 2024 | $17.2 | $79.1 | +361% |
| 2025 | $79.1 | $188.7 | +139% |
| 2026 YTD | $188.7 | $171.6 | -9.1% |
PLTR's yearly returns have swung widely, from +361% in 2024 to −67% in 2022. It's down 9.1% so far in 2026.